> ## Content Index
> Fetch the complete content index at: https://www.coios.me/llms.txt
> Use this file to discover other available public pages before exploring further.

# Semaglutide for weight management and use of other prescribed medicines in Denmark
- URL: https://www.coios.me/semaglutide-for-weight-management-and-use-of-other/
- Published: 2026-10-31T11:16:57.000Z
- Updated: 2026-11-01T07:06:40.000Z
- Description: In 189,392 Danish semaglutide initiators, antiasthmatic use fell below trend (RR 0.82) while anxiolytic use rose (RR 1.16).
- Author: Daniel Ryan
- Tags: Health today, Obesity, diabetes and GLP-1, Denmark, #peer-reviewed, #new, #item, #source-2026-10, #score-74

This Danish register-based interrupted time series included 189,392 adults (68% women) starting semaglutide for weight management in 2022–2024\. Monthly prescriptions for 10 medication classes, 24 months before to 12 months after starting, were compared with pre-initiation trends. At 12 months, use was below projection for antiasthmatics (RR 0.82), analgesics (0.93), antidepressants (0.93) and antihypertensives (0.92). Anxiolytic use rose (RR 1.16) and stayed above projection at two years. Glucose-lowering medicines fell (RR 0.87), but a similar fall appeared in a negative control cohort. The design is observational and relies on projected trends, so the changes are associations, not proven drug effects.

*Why it is interesting: National prescription records show how a widely used obesity drug relates to the wider medicine burden at population scale. The rise in anxiolytic use runs against the direction seen in most other medication classes.*

Source

[Diabetes, Obesity and Metabolism, 25 October 2026](https://doi.org/10.1111/dom.71489?ref=coios.me)

Paper

Impact of Semaglutide Introduction on the Use of Concomitant Medications: An Interrupted Time Series

Authors

Roland N, Sonne H, Mose K, Kjærgaard K, Lundby C, Bramming M et al.

DOI

10.1111/dom.71489

Type

Peer-reviewed article

Design

Nationwide interrupted time series, Danish registers, 189,392 adults initiating semaglutide for weight management Dec 2022–Dec 2024, 24 months pre and 12 months post, with negative control cohort

Verdict

New finding

Driver

[Obesity, diabetes and GLP-1](https://www.coios.me/d-obesity-diabetes/)

Free full text

[Free to read at the publisher](https://doi.org/10.1111/dom.71489?ref=coios.me)